Biosimilars and implications for pharmacy practice: Ready or not, here they come!
US Food & Drug Administration. Novel Drug Approvals for 2018. https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm592464.htm (accessed Mar 20, 2019).
Daller J. Biosimilars: A consideration of the regulations in the United States and European union. Regul Toxicol Pharm. 2016;76:199-208. https://doi.org/10.1016/j.yrtph.2015.12.013
Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. Manage Decis Econ. 2007;28(4-5):439-451. https://doi.org/10.1002/mde.1352
CNBC. FDA approves Novartis' $2.1 million gene therapy — making it the world's most expensive drug. https://www.cnbc.com/2019/05/24/fda-approves-novartis-2-million-spinal-muscular-atrophy-gene-therapy.html (accessed May 21, 2019).
Li WB, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7(5):530-544. https://doi.org/10.3390/ph7050530
Association for Accessible Medications. 2018 Generic Drug Access and Savings in the U.S. https://accessiblemeds.org/sites/default/files/2018_aam_generic_drug_access_and_savings_report.pdf (accessed Jul 26, 2019).
U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry. https://www.fda.gov/media/124907/download (accessed Aug 14, 2019).
Association for Accessible Medications. 2019 Generic Drug Access and Savings in the U.S. https://accessiblemeds.org/resources/blog/2019-generic-drug-and-biosimilars-access-savings-us-report (accessed Jul 26, 2019).
US Food & Drug Administration. Biologics License Applications (BLA) Process (CBER). https://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicenseapplicationsblaprocess/default.htm (accessed Dec 26, 2018).
European Medicines Agency and European Commission. Biosimilars in the EU: Information guide for healthcare professionals. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf (accessed Jul 2, 2019).
Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: Development and evolution of the regulatory pathways. Drug Des Devel Ther. 2017;11:1509-1515. https://doi.org/10.2147/DDDT.S130318
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter, D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102-112. https://doi.org/10.18553/jmcp.2019.25.1.102
Aladul MI, Fitzpatrick RW, Chapman SR. Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: result of a uk web-based survey. BioDrugs. 2017;31(5):439-446. https://doi.org/10.1007/s40259-017-0238-1
Cohen JP, Felix AE, Riggs K, Gupta A. Barriers to market uptake of biosimilars in the US. GaBI J. 2014;3(3):108-115. https://doi.org/10.5639/gabij.2014.0303.028
Regulatory Affairs Professionals Society. Access to Biosimilars in EU Expected to Continue to Outpace US and Canada. https://www.raps.org/news-and-articles/news-articles/2018/4/access-to-biosimilars-in-eu-expected-to-continue-t (accessed Jul 26, 2019).
Journal of Clinical Pathways. News: IQVIA Data Show Biosimilars Struggling for Market Share in the US. https://www.journalofclinicalpathways.com/news/iqvia-data-show-biosimilars-struggling-market-share-us (accessed Jul 26, 2019).
Endocrineweb. America’s First Biosimilar Insulin: Coming to Your Drug Store. https://www.endocrineweb.com/news/diabetes/20555-coming-your-drugstore-americas-first-biosimilar-insulin (accessed Jul 31, 2019).
US Food & Drug Administration. Purple Book: Lists of Licensed Biological Products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or (accessed May 15, 2019).
National Conference of State Legislatures. State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars. http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx (accessed Jul 5, 2019).
NBC News. Future is in doubt for cheaper versions of biologic drugs. https://www.nbcnews.com/health/health-news/future-doubt-cheaper-versions-biologic-drugs-n1023211 (accessed Jul 19, 2019).
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Author Self-Archiving Policy
Pharmacy Practice permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.